Loveland to Lead Customer Success and Value Initiatives Procare Solutions, a leader in child care management software, announced the appointment of Sam Loveland as Chief Customer Officer. In this role, Loveland will be responsible for advancing the customer experience and enabling early childhood education providers to maximize the benefits of Procare. https://mma.prnewswire.com/media/2785151/Procare_Solutions_Appoints_Sam_Loveland_as_Chief_Customer_Officer.jpg Loveland brings extensive […]

Artemis Capital Partners (“Artemis”), a Boston-based private equity firm focused exclusively on partnering with differentiated Industrial Tech companies serving the life sciences, aerospace, and defense markets, announced today the acquisition of Millrock Technology Inc. (“Millrock” or “the Company”), an innovator of lyophilization instrumentation and ancillary products. https://mma.prnewswire.com/media/2785235/Millrock_Logo.jpg For over two decades, Millrock has been recognized

NEW YORK, NY / ACCESS Newswire / September 30, 2025 / If you suffered a loss on your Unicycive Therapeutics, Inc. (NASDAQ:UNCY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/unicycive-therapeutics-inc-lawsuit-submission-form?prid=170217&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 30, 2025 / If you suffered a loss on your Unicycive Therapeutics, Inc. (NASDAQ:UNCY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/unicycive-therapeutics-inc-lawsuit-submission-form?prid=170217&wire=1&utm_campaign=26 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 30, 2025 / If you suffered a loss on your Nutex Health Inc. (NASDAQ:NUTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/nutex-health-inc-lawsuit-submission-form?prid=170206&wire=1&utm_campaign=7 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

NEW YORK, NY / ACCESS Newswire / September 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Broadwind, Inc.("Broadwind" or the "Company") (NASDAQ:BWEN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Broadwind and certain of its officers and/or directors have engaged

(Copenhagen:ZEAL), Company announcement – No. 21 / 2025 Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Copenhagen, Denmark, September 30, 2025 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today

NEW YORK, NY / ACCESS Newswire / September 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of aTyr Pharma, Inc. ("aTyr Pharma, Inc.") (NASDAQ:ATYR) concerning possible violations of federal securities laws. On September 15, 2025, aTyr published a press release announcing topline results from the Company’s Phase 3 EFZO-FIT

Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 GlobeNewswire September 30, 2025 Company announcement – No. 21 / 2025 Total number of shares and voting rights in Zealand Pharma as of September 30, 2025 Copenhagen, Denmark, September 30, 2025 – Zealand Pharma A/S (“the Company” or “Zealand Pharma”)

NEW YORK, NY / ACCESS Newswire / September 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Broadwind, Inc.("Broadwind" or the "Company") (NASDAQ:BWEN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Broadwind and certain of its officers and/or directors have engaged